News articles about Lantheus (NASDAQ:LNTH) have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lantheus earned a news sentiment score of 0.28 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.1848014996733 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Lantheus (LNTH) opened at $20.50 on Wednesday. Lantheus has a 12 month low of $9.25 and a 12 month high of $24.45. The firm has a market cap of $770.75, a price-to-earnings ratio of 25.31, a PEG ratio of 1.33 and a beta of 0.95. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.
LNTH has been the topic of a number of recent research reports. Wells Fargo & Co raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Credit Suisse Group upped their price target on shares of Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group increased their target price on shares of Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, November 7th. Finally, ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Lantheus has an average rating of “Buy” and a consensus target price of $24.75.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/lantheus-lnth-earning-positive-news-coverage-report-shows/1895326.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.